Last reviewed · How we verify

NCT03524924: ESCAPE

Edoxaban and Frailty in Senior Individuals

Completed Last updated 10 August 2022
What this trial tests

trial in Atrial Fibrillation in 180 participants. Completed in 31 March 2021.

Timeline
7 January 2018
Primary endpoint
14 January 2021
31 March 2021

Quick facts

Lead sponsorUniversity of Padova
StatusCompleted
Study typeOBSERVATIONAL
Enrollment180
Start date7 January 2018
Primary completion14 January 2021
Estimated completion31 March 2021
Sites1 location across Italy

Conditions studied

Sponsor

University of Padova

Who can join

80 and older, any sex, with Atrial Fibrillation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Edoxaban, has shown in clinical registration trials a significant reduction of major bleeding compared to warfarin, especially in elderly patients. Efficacy and safety of edoxaban will be assessed in a cohort of very elderly patients (≥80 years of age) with NVAF. A secondary analysis will correlate outcomes with frailty defined according to SHARE-FI (not-frail, pre-frail or frail).

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Very Elderly Patients With Atrial Fibrillation Treated With Edoxaban: Impact of Frailty on Outcomes.
    Denas G, Zoppellaro G, Granziera S, Pagliani L, et al · · 2023 · cited 4× · PMID 38939480 · DOI 10.1016/j.jacadv.2023.100569
  2. Very Elderly Patients With Atrial Fibrillation Treated With Edoxaban : Impact of Frailty on Outcomes
    Denas G, Zoppellaro G, Granziera S, Pagliani L, et al · · 2023

Verify or expand the search:

Other recruiting trials for Atrial Fibrillation

Currently open trials in the same condition.

Other University of Padova trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03524924.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing